Watching June 5-8!
$Barinthus Biotherapeutics (BRNS.US)$ Barinthus Bio To Present VTP-300 Clinical Updates At EASL Congress 2024
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.
More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.
More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
EatSearchers : Cool